UNH:NYSEUnitedHealth Group Incorporated Analysis

UnitedHealth Group is trading near its 20‑day SMA of approximately $381, comfortably above the 50‑day and 200‑day averages, reinforcing a bullish trend despite a bearish MACD histogram. The RSI sits at 61, indicating momentum is still intact without being overbought, and volume remains stable, supporting the price advance toward the $404 resistance level. Recent analyst sentiment is strongly positive, with Goldman Sachs adding UNH to its Conviction List and UBS raising its price target to $460, both underscoring confidence in the earnings beat and the upward‑revised 2026 EPS guidance.
Fundamentally, UNH delivers a solid 2% revenue growth rate, a healthy free cash flow generation of $17.7 bn, and a dividend yield of 2.35% backed by a payout ratio of 66%, suggesting dividend sustainability. Valuation metrics show a trailing P/E of 28.4 versus an industry average of 27.4 and a forward P/E of 18.4, indicating the market is pricing in higher future earnings, while the DCF fair value suggests a modest 3‑4% upside, placing the stock in a fair‑valued zone.